Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.
作者信息
Malekzadeh Parisa, Pasetto Anna, Robbins Paul F, Parkhurst Maria R, Paria Biman C, Jia Li, Gartner Jared J, Hill Victoria, Yu Zhiya, Restifo Nicholas P, Sachs Abraham, Tran Eric, Lo Winifred, Somerville Robert Pt, Rosenberg Steven A, Deniger Drew C
机构信息
Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA.
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.
出版信息
J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4.
Abstract
摘要
相似文献
1
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.新抗原筛查确定了上皮癌患者中广泛的TP53突变免疫原性。
J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4.
2
Targeting a neoantigen derived from a common mutation.靶向一种常见突变衍生的新抗原。
Science. 2021 Mar 5;371(6533). doi: 10.1126/science.abc8697. Epub 2021 Mar 1.
3
4
Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.改变的 HLA-A2 限制性 TP53 表位诱导针对肝细胞癌的特异性 CTL 细胞毒性。
Eur J Immunol. 2023 May;53(5):e2250054. doi: 10.1002/eji.202250054. Epub 2023 Feb 28.
5
Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.头颈部癌症患者循环中 p53 野生型表位特异性 T 细胞的表型。
Sci Rep. 2018 Jul 16;8(1):10716. doi: 10.1038/s41598-018-29067-5.
6
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.来自抗原阴性宿主的有效的 NY-ESO-1 特异性 MHC II 限制性 T 细胞受体可增强肿瘤消退。
J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10.
7
Targeting p53 as a general tumor antigen.将p53作为一种通用肿瘤抗原进行靶向治疗。
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11993-7. doi: 10.1073/pnas.92.26.11993.
8
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.针对独特和共享致癌基因的新抗原反应性 T 细胞的增强检测，用于个性化癌症免疫治疗。
JCI Insight. 2018 Oct 4;3(19):122467. doi: 10.1172/jci.insight.122467.
9
10
Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.鉴定针对 mismatched HLA Class I 导致严重急性移植物抗宿主病的协调的 CD8 和 CD4 T 细胞反应。
Biol Blood Marrow Transplant. 2012 Feb;18(2):210-9. doi: 10.1016/j.bbmt.2011.10.018. Epub 2011 Oct 19.
引用本文的文献
1
In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer.框内种系TP53变异会损害p53寡聚化并易患癌症。
Sci Rep. 2025 Aug 19;15(1):30459. doi: 10.1038/s41598-025-14684-8.
2
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.新抗原驱动的个性化肿瘤治疗：从发现到临床应用的最新进展
Chin Med J (Engl). 2025 Sep 5;138(17):2057-2090. doi: 10.1097/CM9.0000000000003708. Epub 2025 Aug 4.
3
Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRAS neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors.靶向HLA-A*11:01限制性KRAS新抗原且不交叉识别自身抗原RAB7B的T细胞受体在实体瘤中的治疗潜力
J Immunother Cancer. 2025 Jul 18;13(7):e011863. doi: 10.1136/jitc-2025-011863.
4
T cells in cancer: mechanistic insights and therapeutic advances.癌症中的T细胞：机制洞察与治疗进展
Biomark Res. 2025 Jul 15;13(1):97. doi: 10.1186/s40364-025-00807-w.
5
A free energy perturbation-assisted machine learning strategy for mimotope screening in neoantigen-based vaccine design.一种用于基于新抗原的疫苗设计中模拟表位筛选的自由能微扰辅助机器学习策略。
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf254.
6
Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions.用于急性淋巴细胞白血病的新抗原特异性癌症疫苗——挑战、机遇与未来方向
Cancer Immunol Immunother. 2025 Jun 23;74(8):248. doi: 10.1007/s00262-025-04107-y.
7
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.突变型p53特异性CD8TCR疗法联合CD4TCR可预防癌症复发和微转移灶的生长。
Oncoimmunology. 2025 Dec;14(1):2514041. doi: 10.1080/2162402X.2025.2514041. Epub 2025 Jun 14.
8
Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood.从外周血中快速富集祖细胞耗竭的新抗原特异性CD8 T细胞。
bioRxiv. 2025 May 15:2025.05.11.653315. doi: 10.1101/2025.05.11.653315.
9
Identification of shared neoantigens derived from frameshift mutations in the gene.鉴定该基因中由移码突变产生的共享新抗原。
Front Immunol. 2025 May 15;16:1574955. doi: 10.3389/fimmu.2025.1574955. eCollection 2025.
10
Bispecific antibody targeting shared indel-derived neoantigen of APC.靶向抗原呈递细胞（APC）共享的插入缺失衍生新抗原的双特异性抗体。
Front Immunol. 2025 May 15;16:1574958. doi: 10.3389/fimmu.2025.1574958. eCollection 2025.
本文引用的文献
1
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.针对独特和共享致癌基因的新抗原反应性 T 细胞的增强检测，用于个性化癌症免疫治疗。
JCI Insight. 2018 Oct 4;3(19):122467. doi: 10.1172/jci.insight.122467.
2
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.免疫识别导致转移性乳腺癌完全持久消退的体细胞突变。
Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4.
3
T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.T 细胞对人卵巢癌中“热点”突变和独特新抗原的反应。
Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.
4
Comprehensive Characterization of Cancer Driver Genes and Mutations.全面描绘癌症驱动基因和突变。
Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
5
Why are there hotspot mutations in the TP53 gene in human cancers?人类癌症中 TP53 基因为何存在热点突变？
Cell Death Differ. 2018 Jan;25(1):154-160. doi: 10.1038/cdd.2017.180. Epub 2017 Nov 3.
6
Putting p53 in Context.将p53置于背景中考虑。
Cell. 2017 Sep 7;170(6):1062-1078. doi: 10.1016/j.cell.2017.08.028.
7
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.病毒诱导的上皮癌成功免疫治疗中免疫原性肿瘤抗原的格局
Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.
8
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.针对癌症中突变型KRAS的T细胞转移疗法。
N Engl J Med. 2016 Dec 8;375(23):2255-2262. doi: 10.1056/NEJMoa1609279.
9
Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.肿瘤和新抗原反应性T细胞受体可根据其在新鲜肿瘤中的频率来识别。
Cancer Immunol Res. 2016 Sep 2;4(9):734-43. doi: 10.1158/2326-6066.CIR-16-0001. Epub 2016 Jun 28.
10
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.使用睡美人转座子/转座酶系统稳定、非病毒表达突变的肿瘤新抗原特异性T细胞受体
Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.
Zotero 插件